Naltrexone Therapy Fed-State Dosing for Higher Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prescribing information for naltrexone and naltrexone/bupropion therapies does not account for food effects on drug bioavailability, leading to suboptimal efficacy in treating conditions like overweight and obesity.
Innovation Solution
Administer naltrexone and bupropion with food to increase bioavailability, specifically through high-fat meals, enhancing the C max and AUC of these drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naltrexone and bupropion are administered without food, then the treatment follows standard prescribing information, but the bioavailability and efficacy of the drugs are suboptimal
Solution Approach 1:
The patent changes the parameter of food intake condition from fasting (standard) to fed state (with food), which significantly increases drug bioavailability. Clinical trials showed Cmax increased by 91-271% and AUC by 70-107% when administered with food, resolving the contradiction between standard administration and optimal efficacy
2Reliability
If a high fat, high calorie diet is administered with naltrexone and bupropion, then the bioavailability and efficacy of the drugs are significantly improved, but this contradicts typical dietary restrictions recommended for weight loss treatments
Solution Approach 1:
The patent converts the typically harmful effect of high fat, high calorie diet (which would counteract weight loss goals) into a beneficial factor that significantly enhances drug bioavailability. By taking the drugs with such meals, patients achieve both improved pharmacokinetics (Cmax 91-271% increase, AUC 70-107% increase) and weight loss outcomes, effectively converting a dietary restriction requirement into a flexible administration guideline
Data Source
AI summary
Disclosed are compositions, uses, methods and kits for increasing drug bioavailability in a naltrexone therapy.